Several Actionable Targets Identified in Testicular Cancer

Video

This video highlights recent research in cisplatin-resistant testicular cancer, including a study on whole exome sequencing that revealed several actionable targets.

In this video, Aditya Bagrodia, MD, of the University of Texas Southwestern Medical Center, discusses recent research in germ cell tumors.

A recent study that used whole exome sequencing in platinum-resistant disease revealed that many of these patients have actionable targets.

Bagrodia, who gave a presentation on this topic at the 2017 Genitourinary Cancers Symposium in Orlando, Florida, also looks ahead toward trials examining the potential of different immunotherapies in this setting.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content